These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18628568)

  • 1. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications.
    Lopes-Virella MF; Carter RE; Gilbert GE; Klein RL; Jaffa M; Jenkins AJ; Lyons TJ; Garvey WT; Virella G;
    Diabetes Care; 2008 Oct; 31(10):2006-12. PubMed ID: 18628568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.
    Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
    Diabetes; 1999 Feb; 48(2):383-90. PubMed ID: 10334318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort.
    Hunt KJ; Baker NL; Cleary PA; Klein R; Virella G; Lopes-Virella MF;
    Diabetes Care; 2015 Jul; 38(7):1281-9. PubMed ID: 25852210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.
    Polak JF; Backlund JY; Cleary PA; Harrington AP; O'Leary DH; Lachin JM; Nathan DM;
    Diabetes; 2011 Feb; 60(2):607-13. PubMed ID: 21270271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
    Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
    Diabetes Care; 1999 Jan; 22(1):99-111. PubMed ID: 10333910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes.
    Moussavi N; Renier G; Roussin A; Mamputu JC; Buithieu J; Serri O
    Diabetes Obes Metab; 2004 Jan; 6(1):69-77. PubMed ID: 14686966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
    Lyons TJ; Jenkins AJ; Zheng D; Klein RL; Otvos JD; Yu Y; Lackland DT; McGee D; McHenry MB; Lopes-Virella M; Garvey WT;
    Diabet Med; 2006 Sep; 23(9):955-66. PubMed ID: 16922701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort.
    Klein RL; Hunter SJ; Jenkins AJ; Zheng D; Semler AJ; Clore J; Garvey WT;
    Diabetes Care; 2003 May; 26(5):1439-48. PubMed ID: 12716802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.
    Nathan DM; Lachin J; Cleary P; Orchard T; Brillon DJ; Backlund JY; O'Leary DH; Genuth S; ;
    N Engl J Med; 2003 Jun; 348(23):2294-303. PubMed ID: 12788993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes.
    Lopes-Virella MF; McHenry MB; Lipsitz S; Yim E; Wilson PF; Lackland DT; Lyons T; Jenkins AJ; Virella G;
    Atherosclerosis; 2007 Feb; 190(2):359-69. PubMed ID: 16530770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes.
    Leinonen ES; Hiukka A; Hurt-Camejo E; Wiklund O; Sarna SS; Mattson Hultén L; Westerbacka J; Salonen RM; Salonen JT; Taskinen MR
    J Intern Med; 2004 Aug; 256(2):119-27. PubMed ID: 15257724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    JAMA; 2003 Oct; 290(16):2159-67. PubMed ID: 14570951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes.
    Baker NL; Hunt KJ; Stevens DR; Jarai G; Rosen GD; Klein RL; Virella G; Lopes-Virella MF;
    Diabetes Care; 2018 Jan; 41(1):128-135. PubMed ID: 29118060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.
    Lopes-Virella MF; Hunt KJ; Baker NL; Lachin J; Nathan DM; Virella G;
    Diabetes; 2011 Feb; 60(2):582-9. PubMed ID: 20980456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.
    de Vries R; Dallinga-Thie GM; Smit AJ; Wolffenbuttel BH; van Tol A; Dullaart RP
    Diabetologia; 2006 Feb; 49(2):398-404. PubMed ID: 16374627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.
    Purnell JQ; Zinman B; Brunzell JD;
    Circulation; 2013 Jan; 127(2):180-7. PubMed ID: 23212717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC.
    Genuth SM; Backlund JY; Bayless M; Bluemke DA; Cleary PA; Crandall J; Lachin JM; Lima JA; Miao C; Turkbey EB;
    Diabetes; 2013 Oct; 62(10):3561-9. PubMed ID: 23520132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrovascular reactivity, intima-media thickness, and nephropathy presence in patients with type 1 diabetes.
    Kozera GM; Wolnik B; Kunicka KB; Szczyrba S; Wojczal J; Schminke U; Nyka WM; Bieniaszewski L
    Diabetes Care; 2009 May; 32(5):878-82. PubMed ID: 19228874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carotid intima-media thickness and its relations with the complications in patients with type 1 diabetes mellitus.
    Gül K; Ustün I; Aydin Y; Berker D; Erol K; Unal M; Barazi AO; Delibaşi T; Güler S
    Anadolu Kardiyol Derg; 2010 Feb; 10(1):52-8. PubMed ID: 20150006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial.
    Lin J; Glynn RJ; Rifai N; Manson JE; Ridker PM; Nathan DM; Schaumberg DA
    Diabetes Care; 2008 Dec; 31(12):2338-43. PubMed ID: 18796620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.